Acurx Pharmaceuticals Files 8-K on Financials
Ticker: ACXP · Form: 8-K · Filed: May 15, 2024 · CIK: 1736243
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: ACRX
TL;DR
ACRX filed an 8-K with financial updates. Check it out.
AI Summary
Acurx Pharmaceuticals, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company incorporated in Delaware and headquartered in Staten Island, NY.
Why It Matters
This 8-K filing provides an update on Acurx Pharmaceuticals' financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine financial disclosure and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- May 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 259 Liberty Avenue, Staten Island, NY 10305 (address) — Principal executive offices
- 917-533-1469 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Acurx Pharmaceuticals, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 15, 2024.
In which state is Acurx Pharmaceuticals, Inc. incorporated?
Acurx Pharmaceuticals, Inc. is incorporated in Delaware.
What is the business address of Acurx Pharmaceuticals, Inc.?
The business address of Acurx Pharmaceuticals, Inc. is 259 Liberty Avenue, Staten Island, NY 10305.
What is the telephone number for Acurx Pharmaceuticals, Inc.?
The telephone number for Acurx Pharmaceuticals, Inc. is (917) 533-1469.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-05-15 07:13:05
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ACXP The Nasdaq Stock Mar
Filing Documents
- tm2414469d1_8k.htm (8-K) — 24KB
- tm2414469d1_ex99-1.htm (EX-99.1) — 52KB
- 0001104659-24-061579.txt ( ) — 254KB
- acxp-20240515.xsd (EX-101.SCH) — 3KB
- acxp-20240515_lab.xml (EX-101.LAB) — 33KB
- acxp-20240515_pre.xml (EX-101.PRE) — 22KB
- tm2414469d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On May 15, 2024, Acurx Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2024 and providing a business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated May 15, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized. Acurx Pharmaceuticals, Inc. Date: May 15, 2024 By: /s/ David P. Luci Name: David P. Luci Title: President and Chief Executive Officer